Chang Chen, Ph.D., Professor
-
Professor, Principal Investigator at State Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences (CAS)
Professor, University of Chinese Academy of Sciences
Vice Director, National Laboratory of Biomacromolecules (2012-2023)
Distinguished Professor of CAS
Chief Scientist of National Key R&D Program of China (2017-2022, 2022-2027)
Chief Scientist of "National Basic Research Program of China, 973 Program" (2006-2010)
Research Interests: Redox biology, Aging, Traditional Chinese medicine
Email: changchen@ibp.ac.cn
Tel: 010-64888406
Address: 15 Datun Road, Chaoyang District, Beijing, 100101, China
Chinese personal homepage
- Biography
1986 - 1990 B.S., Nankai University, Tianjin, China
1990 - 1993 M.S., Beijing Normal University, Beijing, China
1993 - 1996 Ph.D., Peking University, Beijing, China
1996 - 1998 Assistant Professor, Institute of Biophysics, CAS
1998 - 2000 Associate Professor, Institute of Biophysics, CAS Visiting Scientist in the Institute of Food Research, Norwich, UK (The Royal Society K.C. Wong Research Fellowship)
2000 - Principle Investigator (PI ) (2004, full professor. Institute of Biophysics, CAS.)
2004 - 2005 Visiting Scientist, Center for Cancer Research, the Medical Research Council, Cambridge, UK
2015 - Distinguished Professor, University of Chinese Academy of Sciences
2015 - Member, CAS Centre for Excellence in Biomacromolecules
2018 Visiting Scientist, National Institute of Neurological Disorders and Stroke (NINDS), NIH.
2012 - 2023 Vice Director of National Laboratory of Biomacromolecules
- Awards
2026 Ewha Global Fellow (EGF), Ewha Womans University, 2027-2029
2023 "Four-Good" CPC Member of Central Party and State Organs
2016 Outstanding Member of the Communist Party of China of the CAS
2015 Special Government Allowances of the State Council
2014 Outstanding Contribution, CAS-Beijing
2012 National Outstanding Young Scientists
2006 Young Investigator Award, Society for Free Radical Research (SFRR)-Asia
1998 Royal Society K.C. Wong Fellowship, UK
1997 Young Scientist Innovation Award, CAS, China
- Membership in Academies & Societies
2025 - 2026 President of Society for Free Radical Research (SFRR)-Asia
2021 - 2029 President of the Commission for Redox Biology and Medicine, Biophysical Society of China
2006 - 2021 Vice President of the Commission for Free Radical Biology and Medicine, Biophysical Society of China
2018 - 2022 Council Member, the Chinese Society of Biochemistry and Molecular Biology
2018 - 2019 Council Member, the Commission for Aging Cell Biology of the Chinese Society of Cell Biology
2017 - 2021 President, the Commission for Woman Scientists of the Biophysical Society of China
2017 - 2021 Vice President, the Commission for Aging Biology of the Biophysical Society of China
2017 - Present Council Member, the Biophysical Society of China
2017 - 2020 Council Member, Committee of Anti-aging, China Association of Gerontology and Geriatrics
2013 - 2017 Standing Committee Member, the Biophysical Society of China, Deputy General Secretary
2010 - Present Dissertation Committee, Institute of Biophysics, CAS
2008 - 2012 Head of Professional Women Association, Institute of Biophysics, CAS
2006 - Present Council Member of SFRR-Asia
2006 - Present Education Committee, Institute of Biophysics, CAS
2000 - 2006 Chinese Society for Cell Biology, Council Member
- Research Interests

Reactive oxygen species and reactive nitrogen species (ROS and RNS) have critical biological functions essential for normal physiology. However, overproduction or deficiency result in impaired homeostasis and is associated with pathology, such as aging, cancer, atherosclerosis, neurodegenerative diseases, obesity, and diabetes. Our research has been focused on the crosstalk between these small molecules and macromolecules, trying to explore the relationship between protein function and cellular redox status. Based on it, try to find out effective approach to maintain cellular redox homeostasis and apply for good health. We are also interested in the working mechanism of traditional Chinese medicine (TCM) and its application.
The Ongoing Projects:
1. To explore Redox network - Redox map - Redox signaling: Through whole genome screening, we aim to identify new redox regulatory genes to elucidate the composition of redox family and the crosstalk between redox active small molecules and biomacromolecules. With the help of redox-specific probes, we are trying to draw high-resolution redox maps of cells to obtain a basic understanding of precise cellular redox states under various physiological, pathological and stress conditions. Furthermore, we continue illustrating the mechanism of redox signaling, particularly nitric oxide and S-nitros(yl)ation and other thiol modification in cellular quality control, aging and age-related diseases.
2. To explore Redox stress and Aging: Why anti-aging by antioxidant intervention does not work as expected according to the Free radical theory of aging? Our hypothesis is that the physiological function of redox stress in anti-aging process was neglected and the antioxidant intervention is not based on the precision cellular redox nature. We then proposed the concept of Precision Redox and the "5R" principles as the key for antioxidant pharmacology, i.e., Right species, Right place, Right time, Right level and Right target as guidelines for redox medicine development. Furthermore, we have found that the Redox-stress Response Capacity (RRC) decay is a substantive characteristic of aging and have discovered an insulin-resistance-like phenomenon in senescent cells, termed Redox-stress Response Resistance (RRR). We further identified the point of transition between eustress and distress, and named it as Redox-stress Signalling Threshold (RST), which is not fixed but modifiable. Based on these RRC-RRR-RST novel concepts of redox response in aging, we advocates a proactive health strategy: elevation of RST through early stage stimulation to potentiate RRC while diminishing RRR, thereby delaying the aging process. We proposed that anti-aging should better start from the early stage of life.
3. The scientific connotation of traditional Chinese medicine (TCM) and its application. We have demonstrated the mechanisms of the effect of L. barbarum on "muscle and bone strengthening and anti-aging" as recorded in "Ben Cao Gang Mu". Our study revealed the molecular mechanism of the effects of L. barbarum extract on preventing age-related osteoporosis, enhancing skeletal muscle endurance, preventing age-related muscle stem cell loss and promoting whitening. The research results will provide scientific basis for the development of effective ingredients of L. barbarum into clinical drugs, and may further provide a research model for the development of other traditional Chinese medicine.
4. Function, mechanism and the translational research of S-nitrosoglutathione reductase (GSNOR) and phosphatidylinositol 4-kinase type IIα (PI4KIIα). Our results demonstrate that GSNOR might be a new potential target for the treatment of age-related obesity (Nat Commun. 2026), age-related cognitive impairment (J Neurosci. 2017), cardiovascular diseases (J Mol Cell Cardiol. 2017; Redox Biol. 2018; Redox Biol. 2019) and antiviral innate immunity by restricting TANK-binding kinase 1 (TBK1) cysteine S-nitrosation (Redox Biol. 2021) and specific GSNOR activator and inhibitor are under development. About the study of PI4K, based on our previous work about the structure and function of PI4KIIα (Oncogene, 2010; Protein Cell, 2014; Nature Communications, 2014), PI-273, a substrate-competitive, specific small-molecule inhibitor of PI4KIIα was identified (Cancer Res. 2017) and the translational research is undergoing.
- Grants
- Selected Publications
1. Sun C, He Y, Xiao F, Chen C*. Naringenin alleviates age-related bone loss by targeting Runx2. Br J Pharmacol. 2026 Aug 16:1-18. Online ahead of print.
2. Qiao X#, Xie T#, Zhang Y, Sun C, Wu X, Chen Y, Yao Q, Shi H, Li S, Zhao H, Wang T, Meng J, Zhou L, Niu M, Hu Y, Liu H, Chen C*. S-nitrosoglutathione reductase GSNOR drives age-related obesity by promoting adipose tissue whitening through de-nitrosation of Beclin-1. Nat Commun. 2026 Feb 23;17(1):3059.
3. Ye A, Yu S, Du M, Zhou D, He J*, Chen C*. cxcl18b-defined transitional state-specific nitric oxide drives injury-induced Müller glia cell-cycle re-entry in the zebrafish retina. eLife. 2026 Jan 21;14:RP106274.
4. Meng J#, Li X#, Hu M, Qiao X, Li S, Huang Y, Chen C*. ATAD3A deficiency induces oxidative eustress via the complex I reverse electron transport. Free Radic Biol Med. 2025 Dec 16;241:137-149.
5. Chu B#, Qiao X#, Ye H#, Cui X, Zhang S, Su W, Zhang Y, Sun C, Wu X, Wang T, Li H, Wu J, Huang Z*, Chen C*. S-nitros(yl)ation of CaMKIIα and its precision redox regulation by SNOTAC plays a critical role in learning and memory. Redox Biol. 2025 Oct; 86:103784.
6. Sun C, He Y, Chen X, Ding K*, Chen C*. Lycium barbarum Polysaccharide Ameliorates Hindlimb Unloading-Induced Bone Loss by Targeting Noggin. FASEB J. 2025 Jul 15;39(13):e70795.
7. Su LY#, Jiao L#, Liu Q#, Qiao X#, Xie T, Ma Z, Xu M, Ye MS, Yang LX, Chen C*, Yao YG*. S-nitrosoglutathione reductase alleviates morphine analgesic tolerance by restricting PKCα S-nitrosation. Redox Biol. 2024 Sep;75:103239.
8. Ou Q#, Qiao X#, Li Z#, Niu L, Lei F, Cheng R, Xie T, Yang N, Liu Y, Fu L, Yang J, Mao X, Kou X, Chen C*, Shi S*. Apoptosis releases hydrogen sulfide to inhibit Th17 cell differentiation. Cell Metab. 2024 Jan 2; 36(1):78-89.e5.
9. Lv Z#, Meng J#, Yao S#, Xiao F#, Li S, Shi H, Cui C, Chen K, Luo X*, Ye Y*, Chen C*. Naringenin improves muscle endurance via activation of the Sp1-ERRγ transcriptional axis. Cell Reports. 2023 Nov 28;42(11):113288.
10. Qiao, X#, Kang, L#, Shi, C#, Ye A#, Wu D, Huang Y, Deng M, Wang J, Zhao Y*, Chen C*. Exploring the precision redox map during fasting-refeeding and satiation in C. elegans. Stress Biol. 2023 3(1), 17.
11. Guo M#, Qiao X#, Wang Y#, Li ZH#, Shi C, Chen Y, Kang L, Chen C*, Zhou XL*. Mitochondrial translational defect extends lifespan in C. elegans by activating UPRmt. Redox Biol. 2023 July;63:102722.
12. Meng J, Wang Y, Lv Z, Qiao X, Ye A, Zhu Q, Chen C*. Redox-stress response resistance (RRR) mediated by hyperoxidation of peroxiredoxin 2 in senescent cells. Sci China Life Sci. 2023 Oct;66(10):2280-2294.
13. Sun C#, Chen X#, Yang S, Jin C, Ding K*, Chen C*. LBP1C-2 from Lycium barbarum alleviated age-related bone loss by targeting BMPRIA/BMPRII/Noggin. Carbohyd Polym. 2023, 310: 120725.
14. Zhang Y#, Qiao X#,*, Liu L#, Han W, Liu Q, Wang Y, Xie T, Tang Y, Wang T, Meng J, Ye A, He S, Chen R*, Chen C*. Long noncoding RNA MAGI2-AS3 regulates the H2O2 level and cell senescence via HSPA8. Redox Biol. 2022, Aug; 54:102383.
15. Qiao X, Zhang Y, Ye A, Zhang Y, Xie T, Lv Z, Shi C, Wu D, Chu B, Wu X, Zhang W, Wang P, Liu GH, Wang CC, Wang L*, Chen C*. ER reductive stress caused by Ero1α S-nitrosation accelerates senescence. Free Radic Biol Med. 2022 Feb 20;180:165-178.
16. Meng J, Lv Z, Wang Y, Chen C*. Identification of the redox-stress signaling threshold (RST): Increased RST helps to delay aging in C. elegans. Free Radic Biol Med. 2022 Jan;178:54-58.
17. Liu Q#, Gu T#, Su LY#, Jiao L, Qiao X, Xu M, Xie T, Yang LX, Yu D, Xu L, Chen C*, Yao YG*. GSNOR facilitates antiviral innate immunity by restricting TBK1 cysteine S-nitrosation. Redox Biol. 2021 Nov;47:102172.
18. Deng H#, Qiao X#, Xie T, Fu W, Li H, Zhao Y, Guo M, Feng Y, Chen L, Zhao Y, Miao L, Chen C*, Shen K*, Wang X*. SLC-30A9 is required for Zn2+ homeostasis, Zn2+ mobilization, and mitochondrial health. Proc Natl Acad Sci U S A. 2021 Aug 31;118(35):e2023909118.
19. Cai WB, Zhao YJ, Liu L, Cheng Q, Wang J, Shi XL, Yao L, Qiao XH, Zhu Y, Chen C*, Zhang X*. Redox environment metabolomic evaluation (REME) of the heart after myocardial ischemia/reperfusion injury. Free Radic Biol Med. 2021 Sep;173:7-18.
20. Yi W#, Zhang Y#, Liu B#,*, Zhou Y, Liao D, Qiao X, Gao D, Xie T, Yao Q, Zhang Y, Qiu Y, Huang G, Chen Z*, Chen C*, Ju Z*. Protein S-nitrosylation regulates proteostasis and viability of hematopoietic stem cell during regeneration. Cell Rep. 2021 Mar 30;34(13):108922.
21. Meng J, Lv Z, Zhang Y, Wang Y, Qiao X, Sun C, Chen Y, Guo M, Han W, Ye A, Xie T, Chu B, Shi C, Yang S, Chen C*. Precision Redox: The Key for Antioxidant Pharmacology. Antioxid Redox Sign. 2021 May 10;34(14):1069-1082.
22. Meng J#, Lv Z#, Sun C, Qiao X, Chen C*. An extract of Lycium barbarum mimics exercise to improve muscle endurance through increasing type IIa oxidative muscle fibers by activating ERRγ. FASEB J. 2020 Sep;34(9):11460-11473.
23. Zheng WQ#, Zhang Y#, Yao Q#, Chen Y#, Qiao X, Wang ED*, Chen C*, Zhou XL*. Nitrosative stress inhibits aminoacylation and editing activities of mitochondrial threonyl-tRNA synthetase by S-nitrosation. Nucleic Acids Res. 2020 Jul 9;48(12):6799-6810.
24. Ban Y#, Liu Y#, Li Y, Zhang Y, Xiao L, Gu Y, Chen S, Zhao B, Chen C*, Wang N*. S-nitrosation impairs KLF4 activity and instigates endothelial dysfunction in pulmonary arterial hypertension. Redox Biol. 2019 Feb;21:101099.
25. Li J, Zhang Y, Zhang Y, Lü S, Miao Y, Yang J, Huang S, Ma X, Han L, Deng J, Fan F, Liu B, Huo Y, Xu Q, Chen C*, Wang X*, Feng J*. GSNOR modulates hyperhomocysteinemia-induced T cell activation and atherosclerosis by switching Akt S-nitrosylation to phosphorylation. Redox Biol. 2018 Jul;17:386-399.
26. Li J, Gao Z, Zhao D, Zhang L, Qiao X, Zhao Y, Ding H, Zhang P, Lu J, Liu J, Jiang H, Luo C*, Chen C*. PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells. Cancer Res. 2017 Nov 15;77(22):6253-6266.
27. Zhang Y, Wu K, Su W, Zhang DF, Wang P, Qiao X, Yao Q, Yuan Z, Yao YG, Liu G, Zhang C, Liu L, Chen C*. Increased GSNOR Expression during Aging Impairs Cognitive Function and Decreases S-Nitrosation of CaMKIIα. J Neurosci. 2017 Oct 4;37(40):9741-9758.
28. Li Y, Zhang Y, Wang L, Wang P, Xue Y, Li X, Qiao X, Zhang X, Xu T, Liu G, Li P, Chen C*. Autophagy impairment mediated by S-nitrosation of ATG4B leads to neurotoxicity in response to hyperglycemia. Autophagy. 2017 Jul 3;13(7):1145-1160.
29. Meng J, Lv Z, Qiao X, Li X, Li Y, Zhang Y, Chen C*. The decay of Redox-stress Response Capacity is a substantive characteristic of aging: Revising the redox theory of aging. Redox Biol. 2017 Apr;11:365-374.
30. Gao L#, Zhang Y#, Wang Y, Qiao X, Zi J, Chen C*, Wan Y*. Reduction of PCN biosynthesis by NO in Pseudomonas aeruginosa. Redox Biol. 2016 Aug;8:252-8.
31. Zhou Q#, Li J#, Yu H, Zhai Y, Gao Z, Liu Y, Pang X, Zhang L, Schulten K*, Sun F*, Chen C*. Molecular insights into the membrane-associated phosphatidylinositol 4-kinase IIα. Nat Commun. 2014 Mar 28;5:3552.
32. Li J, Zhang L, Gao Z, Kang H, Rong G, Zhang X, Chen C*. Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy. Protein Cell. 2014 Jun;5(6):457-68.
33. Sun F, Li J, Chen C*. Puzzle out the regulation mechanism of PI4KIIα activity. Sci China Life Sci. 2014 Jun;57(6):636-8.
34. Zhang X#, Huang B#, Zhang L, Zhang Y, Zhao Y, Guo X, Qiao X, Chen C*. SNObase, a database for S-nitrosation modification. Protein Cell. 2012 Dec;3(12):929-33.
35. Zhang X#, Huang B#, Chen C*. SNO spectral counting (SNOSC), a label-free proteomic method for quantification of changes in levels of protein S-nitrosation. Free Radic Res.
Patents
1. Chang Chen, Chuanxin Sun. The application of Lycium barbarum polysaccharides in the preparation of drugs for the prevention and/or treatment of bone loss. Patent No. ZL2025107389199. (China)
2. Chang Chen, Chuanxin Sun. Drug compositions and their uses in the prevention and/or treatment of osteoporosis. Patent Application No. 202511567391X. (China)
3. Chang Chen, Chuanxin Sun. Medications for osteoporosis and their preparation methods and applications. Patent Application No. 2025115679441. (China)
4. Chang Chen, Chuanxin Sun. The use of Lycium barbarum extract in the prevention and/or treatment of age-related retinopathy. Patent Application No. 2025117333062. (China)
5. Chang Chen, Chuanxin Sun. The uses of Lycium barbarum extract in enhancing heat production capacity and/or improving metabolic disorders. Patent Application No. 2025117545579. (China)
6. Kan Ding, Chang Chen, Chuanxin Sun, Wenfeng Liao. Lycium barbarum sulfated polysaccharides and their preparation methods and applications. Patent Application No. 2025108445872. (China)
7. Chang Chen, Kan Ding, Xingke Yang, Xinhua Qiao, Can Jin, Chuanxin Sun, Wensheng Han, Ting Xie, Chang Shi. The uses of compositions containing Lycium barbarum polysaccharides. Patent Application No. 2023109298424.
8. Chang Chen, Kan Ding, Xingke Yang, Chuanxin Sun, Xia Chen, Can Jin. COMPOSITION COMPRISING HOMOGENEOUS POLYSACCHARIDE OR DERIVATIVE THEREOF AND METHOD OF USING THE SAME TO PREVENT AND/OR TREAT BONE LOSS. Patent Application No. PCT/IB2023/000414. Public No. WO 2024/013562 A1. Patent No. ZL2023800537413 (China). Patent Application No. EP 23 767 965.9 (European). Patent No. JP2025-501810(P2025-501810) (Japan).
9. Chang Chen, Kan Ding, Xingke Yang, Jiao Meng, Can Jin, Zhenyu Lv, Chuanxin Sun, Xia Chen. COMPOSITION COMPRISING HOMOGENEOUS POLYSACCHARIDE AND METHOD OF USING THE SAME TO IMPROVE MUSCLE SATELLITE CELLS. Patent Application No.PCT/IB2023/000278. Public No. WO2023223098A1.
10. Chang Chen, Yang Ye, Xingke Yang, Kaixian Chen, Xiaomin Luo, Jiao Meng, Sheng Yao, Zhenyu Lv. COMPOSITION COMPRISING NARINGENIN OR DERIVATIVE THEREOF, METHOD OF MAKING AND METHOD OF USING THE SAME. Patent Application No.PCT/IB2023/000179. Public No. WO2023180813A1.
11. Xiaolin Tong, Chang Chen, The invention relates to an antidepressant drug composition and a preparation method and application. Patent No: ZL201811628807.4, Date of Patent: Dec. 17, 2021. (China)
12. Xiaolin Tong, Chang Chen, The invention relates to a drug composition for treating diabetes and a preparation method and application. Patent No: ZL 201811626580.X, Date of Patent: Oct. 22, 2021. (China)
13. Chang Chen, Jiao Meng, Zhenyu Lv, Chuanxin Sun, Xinhua Qiao, LYCIUM BARBARUM EXTRACTS, RESULTING COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING THE SAME. Patent No. US11, 135, 260 B2, Date of Patent: Oct. 5, 2021 (USA). Patent No. ZL202110023756.8, Date of Patent: Jan. 8, 2022 (China). Patent No.HK40052396. Date of Patent: Sep. 2, 2022 (Hong Kong).
14. Chang Chen, Cheng Luo, Hualiang Jiang, Jiangmei Li, Zhen Gao, Dan Zhao, Lunfeng Zhang, Xinhua Qiao, The application of PI-273, the specific inhibitor of PI4KIIα. Patent No: ZL 201510831539.6, Date of Patent: Jan. 29, 2021. (China)
15. Yi Wan, Chang Chen, Lei Gao, Yuying Zhang, Xinhua Qiao, Yan Wang, Method, target and application for NO accumulation to decrease Pseudomonas aeruginosa invasiveness, Patent No: ZL 201510697439.9, Date of Patent: May 17, 2019 (China). Patent No: US 10537593B2, Date of Patent: Jan. 21, 2020 (USA).
16. Chang Chen, Bo Huang, A specific method for detection of thiol modification and its application. Patent No: ZL200910084155.7, Date of Patent: Aug. 28, 2013. (China)
17. Chang Chen, Jiangmei Li "The application of Phosphatidylinositol 4-Kinase Type IIα (PI4KIIα) as a potential target for drug discovery". Patent No: ZL200810104272.0, Date of Patent: May 8, 2013. (China)
(From Chang Chen, October 30, 2026)
